Assertio Holdings Amends Merger Agreement, Increases Tender Offer to $21.80 Cash Per Share

summarizeSummary

Assertio Holdings has entered into an amended merger agreement with Garda Therapeutics, increasing the all-cash tender offer to $21.80 per share and removing the contingent value right.

check_boxKey Events

• Amended Merger Agreement

  Assertio Holdings, Inc. entered into an Amended and Restated Agreement and Plan of Merger with Garda Therapeutics, Inc. and Audi Merger Sub, Inc. on May 1, 2026.

• Increased All-Cash Offer Price

  The offer price for all outstanding shares of Assertio common stock has been increased to $21.80 per share in cash, eliminating the previously included non-tradeable contingent value right. This is up from the original offer of $18.00 per share plus a CVR.

• Board Unanimously Recommends Offer

  Assertio's Board of Directors unanimously approved the amended merger agreement and recommended that stockholders accept the offer and tender their shares.

• Financing Secured

  The transaction is supported by $22.2 million in equity financing from Joseph M. Limber and Brett K.E. Lund, and $130 million in debt financing from Colbeck Capital Management, LLC, ensuring sufficient funds for the acquisition and related obligations.

auto_awesomeAnalysis

Assertio Holdings has finalized an amended merger agreement with Garda Therapeutics, significantly improving the acquisition terms for shareholders. The new all-cash offer of $21.80 per share eliminates the previous contingent value right (CVR) and represents a substantial premium over the prior offer and the company's unaffected stock price. This provides greater certainty and immediate cash value to stockholders. The offer price is also above the company's current trading price and its 52-week high, indicating a favorable exit for investors. The Board's unanimous recommendation underscores the attractiveness of the revised terms, which are supported by fully committed equity and debt financing.